Laformin GV 1mg/500mg/0.2mg Tablet ER
By Laformin GV
Rx
10 Tablet ER in a Strip

Composition
Glimepiride(1mg) + Metformin(500mg) + Voglibose(0.2mg)

Manufacturer - La Renon Healthcare Pvt Ltd
Behind Rajpath Club, Kensville Road, Opp. Infostretch Building, Off S.G. Highway, Ahmedabad- 380059, Gujarat- India

Expires on or after
February, 2026

liver
When using Laformin GV 1mg/500mg/0.2mg Tablet ER, it's important to be cautious if you have liver disease. Patients with liver issues may require a dose adjustment when taking this medication. It's recommended to consult your doctor before starting treatment. Typically, Laformin GV 1mg/500mg/0.2mg Tablet ER is initiated at a low dose for individuals with mild to moderate liver disease. However, it is advised not to use this medication in patients with severe liver disease. It's essential to prioritize your liver health and seek guidance from a healthcare professional when considering the use of Laformin GV 1mg/500mg/0.2mg Tablet ER.

kidney
Laformin GV 1mg/500mg/0.2mg Tablet ER may not be safe for patients with kidney disease and should be avoided. Consult your doctor before using. Not recommended for those with severe kidney issues.

alcohol
It is risky to drink alcohol with Laformin GV 1mg/500mg/0.2mg Tablet ER.

driving
When taking Laformin GV 1mg/500mg/0.2mg Tablet ER, avoid driving if experiencing low or high blood sugar symptoms that may affect your focus or reaction time.

pregnancy
Laformin GV 1mg/500mg/0.2mg Tablet ER may be unsafe during pregnancy, as animal studies suggest possible harm to the developing baby. Your doctor will assess potential risks and benefits before prescribing. Please consult your doctor.

breastfeeding
Laformin GV 1mg/500mg/0.2mg Tablet ER may not be safe to use while breastfeeding as it can possibly pass into breastmilk and harm the baby.
Habit Forming | No |
Chemical Class | - |
Therapeutic Class | ANTI DIABETIC |
Action Class | - |
₹128
Inclusive of all taxes
Content verified by

Dr. Abdullah Khan
MBBS - General Medicine
Last update on 01-Oct-2024